skip to primary navigationskip to content

Cellular and molecular characterization of breast cancer heterogeneity


Dr Walid Khaled  -  Group Leader                                                            

Fellow at Magdalene College

Member of the Naked Mole-Rat Initiative


Tel:+44- 01223 334035/334029

Fax: +44 1223 334100

( View Walid Khaled's profile on LinkedIn

Follow us on twitter


Due to space constraints we are NOT accepting any AMGEN program applications for 2015. Thank you for your interest.


TNBC, Cancer biology, Cancer therapeutics, Proteomics, Genetic screens.

Investigator biography

I read for my undergraduate degree at the University of Edinburgh followed by a Masters degree at Imperial College, London working with Prof. Eric Lam on the PI3K pathway and cell cycle regulation (2001-2002). I did my PhD training with Prof. Christine Watson, Department of Pathology, University of Cambridge where I focused on the role of Stat6 in mammary gland development (2002-2007). After my PhD, I was awarded a junior research fellowship at King's College, Cambridge (2008-2012). The fellowship allowed me to stay for a short post-doc with Prof. Watson during which I identified a novel cell fate regulator Zfp157 (2007-2009). In 2009 I joined the Sanger Institute to work with Dr. Pentao Liu. During my time at Sanger I worked on the connection between cell fate regulation and breast cancer development particularly focusing on the transcription regulator BCL11A. In October 2013, I was appointed as a University Lecturer and group leader at the Department of Pharmacology, University of Cambridge. In May 2014 I was awarded a CRUK Career Establishment Award to investigate the cellular and molecular drivers of breast cancer heterogeneity with a particular focus on the development of novel therapies for triple negative breast cancer (TNBC). I also have a collaboration with Dr. Ewan St John Smith (Department of Pharmacology) and Dr. Kosuke Yusa (Sanger Institute) to identify tumour suppressor genes in the naked mole-rat using CRISPR/Cas9 technology.